Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

D. Schadendorf*, M. M. Amonkar, M. Milhem, K. Grotzinger, L. V. Demidov, P. Rutkowski, C. Garbe, R. Dummer, J. C. Hassel, P. Wolter, P. Mohr, U. Trefzer, C. Lefeuvre-Plesse, A. Rutten, N. Steven, G. Ullenhag, L. Sherman, F. S. Wu, K. Patel, M. CaseyC. Robert

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study'. Together they form a unique fingerprint.

Medicine & Life Sciences